Open Orphan #ORPH – Testing of anti-viral for treating COVID-19 underway April 23, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that its London-based subsidiary hVIVO has commenced the testing of an anti-viral for treating COVID-19 on behalf of its client Nearmedic International Ltd. hVIVO has initiated work on this contract with Nearmedic International Ltd, a specialist pharmaceutical, biotechnological…

Open Orphan #ORPH – Completion of the compulsory acquisition of remaining hVIVO shares March 9, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, announces that further to the announcement of 28 January 2020, the Company will shortly be posting letters to shareholders of hVIVO plc (“hVIVO”) who did not accept the offer made by the Company on 9 December 2019. The letters confirm completion of…

Shares Magazine Spotlight – Open Orphan lining up for coronavirus fight February 27, 2020 – Posted in: Open Orphan (ORPH)

LSE interview – Cathal Friel refocuses Open Orphan #ORPH as he raises 5m and buys virology specialist hVIVO February 7, 2020 – Posted in: Open Orphan (ORPH)

In a wide-ranging interview with London South East, Open Orphan Executive Chairman Cathal Friel outlines his vision for the business and explains how the combined talents of Open Orphan, hVivo and Venn Life Sciences will create a soon to be profitable pharmaceutical services one-stop shop. Friel says this acquisition is the last however, as he is a major shareholder and he doesn’t want to see his own shareholding diluted along with everyone elses. The focus…

Open Orphan #ORPH presents at Shares Growth and Invention Forum, London – Posted in: Open Orphan (ORPH)

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be attending and presenting at the Shares Growth and Invention Forum on February 11, 2020 at Business Design Centre, London N1, London, N1 0QH. Cathal will be presenting at 15:30 in the Babbage Room. Investors are able to register to attend…

Open Orphan #ORPH – Upcoming Investor Events February 6, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 11th February to 26th March 2020. Cathal Friel, Open Orphan’s Executive Chairman, or Trevor Phillips, CEO, will be in attendance for all…

Proactive Investors interview with the Open Orphan #ORPH team on its future and ‘the lottery ticket’ sitting within hVIVO February 4, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan PLC‘s (LON:ORPH) Cathal Friel speaks to Proactive London’s Andrew Scott following the completion last week of its £5.3mln fundraise. Also in studio is adviser to Open Orphan and founder of hVivo Professor John Oxford. Professor Oxford’s been a leader in the field of vaccine and anti-viral clinical trials for the last 20 years. hVivo, which has recently been acquired by Open Orphan, owns the largest commercial quarantine clinic in northern Europe and…

BRR Media – Open Orphan #ORPH business update – Posted in: Open Orphan (ORPH)

Cathal Friel, Executive Chairman of Open Orphan, provides an update on developments at the company following the successful fundraising, and also introduces Professor John Oxford – a leading expert in the field of virology and an original founder of hVIVO – who will be working with the company as a consultant.

Keeping pace with Open Orphan February 3, 2020 – Posted in: Open Orphan (ORPH)

It’s been an exceptionally busy few months for Open Orphan (ORPH) and its Executive Chairman Cathal Friel. Since reversing into Venn Life Sciences last summer, Open Orphan has set it’s sights on a series of acquisitions to forge a specialist pharmaceutical services group with a focus on orphan drugs. In raising the money to complete the Venn Life Sciences and recent hVIVO acquisitions, Friel has invested over £2m of his own money through his investment…

Sunday Times – Irish firm Open Orphan #ORPH lined up for role in coronavirus fight February 2, 2020 – Posted in: Open Orphan (ORPH)

by Brian Carey An Irish company is on call to play a part in the fight against the spread of the Wuhan coronavirus. Open Orphan, which is listed on the Alternative Investment Market in London, has just completed the purchase of hVivo, a British company which owns the largest commercial quarantine clinic in northern Europe. The 24-bed clinic, attached to St Mary’s Hospital in London, is the only purpose-built commercial quarantine facility of its kind…